Be Familiar With the Latest Monoclonal Antibody to Treat COVID-19

Casirivimab/imdevimab will be the second monoclonal antibody authorized to treat OUTpatients with COVID-19.

This combo will be an alternative to bamlanivimab as a single-dose IV infusion. And more are in the works.

These "mabs" block the virus that causes COVID-19...SARS-CoV-2...from entering cells. And combo products may reduce the chance of developing resistant viral variants.

Practical advice for a better career, with unlimited access to CE

Pharmacy Technician's Letter Canada includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 200+ CE courses, including the popular CE-in-the-Letter
  • Helpful, in-depth Technician Tutorials
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote